0
Original Investigation |

Effect of Micronutrient Supplementation on Disease Progression in Asymptomatic, Antiretroviral-Naive, HIV-Infected Adults in Botswana:  A Randomized Clinical Trial

Marianna K. Baum, PhD1; Adriana Campa, PhD1; Shenghan Lai, MD, MPH5; Sabrina Sales Martinez, MS1; Lesedi Tsalaile, MS2; Patricia Burns, MS, MPH3; Mansour Farahani, MD, PhD3; Yinghui Li, MS1; Erik van Widenfelt, BSc2; John Bryan Page, PhD4; Hermann Bussmann, MD2; Wafaie W. Fawzi, MBBS, DrPH3; Sikhulele Moyo, MPH2; Joseph Makhema, MB, ChB, MRCP2; Ibou Thior, MD2; Myron Essex, DVM, PhD3; Richard Marlink, MD3
[+] Author Affiliations
1Florida International University, R. Stempel College of Public Health and Social Work, Miami
2Botswana Harvard Partnership, Gaborone, Botswana
3Harvard School of Public Health, Boston, Massachusetts
4University of Miami, Miami, Florida
5Johns Hopkins University School of Medicine, Baltimore, Maryland
JAMA. 2013;310(20):2154-2163. doi:10.1001/jama.2013.280923.
Text Size: A A A
Published online

Importance  Micronutrient deficiencies occur early in human immunodeficiency virus (HIV) infection, and supplementation with micronutrients may be beneficial; however, its effectiveness has not been investigated early in HIV disease among adults who are antiretroviral therapy (ART) naive.

Objective  To investigate whether long-term micronutrient supplementation is effective and safe in delaying disease progression when implemented early in adults infected with HIV subtype C who are ART-naive.

Design, Setting, and Participants  Randomized clinical trial of supplementation with either daily multivitamins (B vitamins and vitamins C and E), selenium alone, or multivitamins with selenium vs placebo in a factorial design for 24 months. The study was conducted in 878 patients infected with HIV subtype C with a CD4 cell count greater than 350/μL who were not receiving ART at Princess Marina Hospital in Gaborone, Botswana, between December 2004 and July 2009.

Interventions  Daily oral supplements of B vitamins and vitamins C and E, selenium alone, or multivitamins plus selenium, compared with placebo.

Main Outcomes and Measures  Reaching a CD4 cell count less than 200/μL until May 2008; after this date, reaching a CD4 cell count of 250/μL or less, consistent with the standard of care in Botswana for initiation of ART at the time of the study.

Results  There were 878 participants enrolled and randomized into the study. All participants were ART-naive throughout the study. In intent-to-treat analysis, participants receiving the combined supplement of multivitamins plus selenium had a significantly lower risk vs placebo of reaching CD4 cell count 250/μL or less (adjusted hazard ratio [HR], 0.46; 95% CI, 0.25-0.85; P = .01; absolute event rate [AER], 4.79/100 person-years; censoring rate, 0.92; 17 events; placebo AER, 9.22/100 person-years; censoring rate, 0.85; 32 events). Multivitamins plus selenium in a single supplement, vs placebo, also reduced the risk of secondary events of combined outcomes for disease progression (CD4 cell count ≤250/μL, AIDS-defining conditions, or AIDS-related death, whichever occurred earlier [adjusted HR, 0.56; 95% CI, 0.33-0.95; P = .03; AER, 6.48/100 person-years; censoring rate, 0.90; 23 events]). There was no effect of supplementation on HIV viral load. Multivitamins alone and selenium supplementation alone were not statistically different from placebo for any end point. Reported adverse events were adjudicated as unlikely to be related to the intervention, and there were no notable differences in incidence of HIV-related and health-related events among study groups.

Conclusions and Relevance  In ART-naive HIV-infected adults, 24-month supplementation with a single supplement containing multivitamins and selenium was safe and significantly reduced the risk of immune decline and morbidity. Micronutrient supplementation may be effective when started in the early stages of HIV disease.

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Place holder to copy figure label and caption
Figure 1.
Randomization Flowchart

Flowchart depicts the study participant screening, randomization, disposition, and loss to follow-up by group. Of the 878 participants enrolled and randomized, 872 were included in the primary analysis; data for 6 patients (0.06%) were missing. Total loss to follow-up was 17.5% (153/872), which included those who missed more than 3 monthly visits and were formally declared lost to follow-up; we were unable to contact them, and they did not return for a study visit. This loss to follow-up also included those who moved from the catchment area and those who chose to discontinue participation. Additionally, 7.5% (66/872) had left the study because of pregnancy, for a total loss to follow-up of 25% (219/872) for the 5-year study. χ2 analysis showed that there were no significant differences among the groups in loss to follow-up, (df=3, value 0.74, P=.86). BMI indicates body mass index; HIV, human immunodeficiency virus.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Kaplan-Meier Estimates for Reaching the Primary End Point of CD4 Cell Count of 250/μL or Less by Supplementation Group

The numbers at risk refer to the number of participants at risk entering each 6-month interval by supplementation group.

Graphic Jump Location

Tables

References

CME


You need to register in order to view this quiz.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 1

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Multimedia Related by Topic

Author Interview

Articles Related By Topic
Related Topics
PubMed Articles
Jobs
brightcove.createExperiences();